DRSC/TRiP Functional Genomics Resources

powered by:
logo

back to: DIOPT - Ortholog Prediction Tool / DIOPT for Diseases and Traits


Protein Alignment LRP2 and Lrp2

DIOPT Version :10

Sequence 1:NP_004516.2 Gene:LRP2 / 4036 HGNCID:6694 Length:4655 Species:Homo sapiens
Sequence 2:NP_110454.2 Gene:Lrp2 / 29216 RGDID:68407 Length:4660 Species:Rattus norvegicus


Alignment Length:4665 Identity:3564/4665 - (76%)
Similarity:4079/4665 - (87%) Gaps:15/4665 - (0%)


- Green bases have known domain annotations that are detailed below.


Human     1 MDRGPAAVACTLLLALVACLAPASGQECDSAHFRCGSGHCIPADWRCDGTKDCSDDADEIGCAVV 65
            |:||.||.|..||||:.|||.|.|.|||.|.:|||.:|:||||.||||||:||.||.|||||...
  Rat     1 MERGAAAAAWMLLLAIAACLEPVSSQECGSGNFRCDNGYCIPASWRCDGTRDCLDDTDEIGCPPR 65

Human    66 TCQQGYFKCQSEGQCIPNSWVCDQDQDCDDGSDERQDCSQSTCSSHQITCSNGQCIPSEYRCDHV 130
            :|:.|.|.|.:||.|||:|||||:|:||.||:||:|:|:.:|||:.|:|||||||||||||||||
  Rat    66 SCESGLFLCPAEGTCIPSSWVCDEDKDCSDGADEQQNCAGTTCSAQQMTCSNGQCIPSEYRCDHV 130

Human   131 RDCPDGADENDCQYPTCEQLTCDNGACYNTSQKCDWKVDCRDSSDEINCTEICLHNEFSCGNGEC 195
            .|||||:||.:|.||||:||||.|||||||||:||.||||||||||.|||.:|...||.||:|||
  Rat   131 SDCPDGSDERNCHYPTCDQLTCANGACYNTSQRCDQKVDCRDSSDEANCTTLCSQKEFECGSGEC 195

Human   196 IPRAYVCDHDNDCQDGSDEHACNYPTCGGYQFTCPSGRCIYQNWVCDGEDDCKDNGDEDGCESGP 260
            |.|||||||||||:|.|||..|||.||||:||||.:|:||.|||||||:|||:|:||||||||. 
  Rat   196 ILRAYVCDHDNDCEDNSDERNCNYDTCGGHQFTCSNGQCINQNWVCDGDDDCQDSGDEDGCESN- 259

Human   261 HDVHKCSPREWSCPESGRCISIYKVCDGILDCPGREDENNTSTGKYCSMTLCSALNCQYQCHETP 325
            ...|:|.||||:||.|||||||.|||||:.|||..:||||.::|:.|.|.:||.|||:||||:||
  Rat   260 QSHHRCYPREWACPGSGRCISIDKVCDGVPDCPEGDDENNVTSGRTCGMGVCSVLNCEYQCHQTP 324

Human   326 YGGACFCPPGYIINHNDSRTCVEFDDCQIWGICDQKCESRPGRHLCHCEEGYILERGQYCKANDS 390
            :||.||||||:|||.||||||::|||||||||||||||:|.|||.|.|||||||||||:||::||
  Rat   325 FGGECFCPPGHIINSNDSRTCIDFDDCQIWGICDQKCENRQGRHQCLCEEGYILERGQHCKSSDS 389

Human   391 FGEASIIFSNGRDLLIGDIHGRSFRILVESQNRGVAVGVAFHYHLQRVFWTDTVQNKVFSVDING 455
            |..||:|||||||||:||:|||:||||.||:|||:.:||.|||...||||||.:|.||||.||||
  Rat   390 FSAASVIFSNGRDLLVGDLHGRNFRILAESKNRGMVMGVDFHYQKHRVFWTDPMQEKVFSTDING 454

Human   456 LNIQEVLNVSVETPENLAVDWVNNKIYLVETKVNRIDMVNLDGSYRVTLITENLGHPRGIAVDPT 520
            ||.||:|||||:|||||||||:|||:|||||||||||:|||:|:.||||||||||||||||:|||
  Rat   455 LNTQEILNVSVDTPENLAVDWINNKLYLVETKVNRIDVVNLEGNQRVTLITENLGHPRGIALDPT 519

Human   521 VGYLFFSDWESLSGEPKLERAFMDGSNRKDLVKTKLGWPAGVTLDMISKRVYWVDSRFDYIETVT 585
            |||||||||.||||:||:||||||||||||||.||:|||||:|||::||||||||||:|||||||
  Rat   520 VGYLFFSDWGSLSGQPKVERAFMDGSNRKDLVTTKVGWPAGITLDLVSKRVYWVDSRYDYIETVT 584

Human   586 YDGIQRKTVVHGGSLIPHPFGVSLFEGQVFFTDWTKMAVLKANKFTETNPQVYYQASLRPYGVTV 650
            |||||||||..||||:|||||:||||..|||||||||||:||:||||||||||:|:||||:||||
  Rat   585 YDGIQRKTVARGGSLVPHPFGISLFEEHVFFTDWTKMAVMKASKFTETNPQVYHQSSLRPHGVTV 649

Human   651 YHSLRQPYATNPCKDNNGGCEQVCVLSHRTDNDGLGFRCKCTFGFQLDTDERHCIAVQNFLIFSS 715
            ||:||||.|||||..|||||.|||||||||||.|||:||||.|||:||.||..|:||:|||:|||
  Rat   650 YHALRQPNATNPCGSNNGGCAQVCVLSHRTDNGGLGYRCKCEFGFELDDDEHRCVAVKNFLLFSS 714

Human   716 QVAIRGIPFTLSTQEDVMVPVSGNPSFFVGIDFDAQDSTIFFSDMSKHMIFKQKIDGTGREILAA 780
            :.|:|||||||||||||||||:|:||||||||||||.||:|:||:||.:|:||||||||:|::.|
  Rat   715 KTAVRGIPFTLSTQEDVMVPVTGSPSFFVGIDFDAQHSTVFYSDLSKDIIYKQKIDGTGKEVITA 779

Human   781 NRVENVESLAFDWISKNLYWTDSHYKSISVMRLADKTRRTVVQYLNNPRSVVVHPFAGYLFFTDW 845
            ||:|:||.|.|||||:||||||...||::|:|||||:||.::..||||||:||||.|||:|.:||
  Rat   780 NRLESVECLTFDWISRNLYWTDGGLKSVTVLRLADKSRRQIISNLNNPRSIVVHPTAGYMFLSDW 844

Human   846 FRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWAASRLYWVDAYFDKIEHSTFDGLDRRRLGHI 910
            ||||||||||||||||:|::||:|||||||||||:|||||||||:||||||||.|||||:||||:
  Rat   845 FRPAKIMRAWSDGSHLMPIVNTSLGWPNGLAIDWSASRLYWVDAFFDKIEHSTLDGLDRKRLGHV 909

Human   911 EQMTHPFGLAIFGEHLFFTDWRLGAIIRVRKADGGEMTVIRSGIAYILHLKSYDVNIQTGSNACN 975
            :||||||||.:|.:::|.|||||||||||||:|||:|||||.||:.::|:|:||.::|||||.|:
  Rat   910 DQMTHPFGLTVFKDNVFITDWRLGAIIRVRKSDGGDMTVIRRGISSVMHVKAYDADLQTGSNYCS 974

Human   976 QPTHPNGDCSHFCFPVPNFQRVCGCPYGMRLASNHLTCEGDPTNEPPTEQCGLFSFPCKNGRCVP 1040
            |.||.||||||||||||||||||||||||:|..:.:||||||..||||:|||..||||.||:|||
  Rat   975 QTTHANGDCSHFCFPVPNFQRVCGCPYGMKLQRDQMTCEGDPAREPPTQQCGSLSFPCNNGKCVP 1039

Human  1041 NYYLCDGVDDCHDNSDEQLCGTLNNTCSSSAFTCGH-GECIPAHWRCDKRNDCVDGSDEHNCPTH 1104
            :::.|||||||||||||..||..|||||.|||.|.. |:|||..|.||::|||:|||||.|||||
  Rat  1040 SFFRCDGVDDCHDNSDEHQCGVFNNTCSPSAFACVRGGQCIPGQWHCDRQNDCLDGSDEQNCPTH 1104

Human  1105 APAS-CLDTQYTCDNHQCISKNWVCDTDNDCGDGSDEKNCNSTETCQPSQFNCPNHRCIDLSFVC 1168
            |.:| |..|.:|||||.||.|:|||||||||.||||||||.::.||||:||.||:||||...:||
  Rat  1105 ATSSTCPSTSFTCDNHVCIPKDWVCDTDNDCSDGSDEKNCQASGTCQPTQFRCPDHRCISPLYVC 1169

Human  1169 DGDKDCVDGSDEVGCVLNCTASQFKCASGDKCIGVTNRCDGVFDCSDNSDEAGCPTRPPGMCHSD 1233
            ||||||.|||||.|||||||::|||||.|..||....|||||:||.|||||||||||||||||.|
  Rat  1170 DGDKDCADGSDEAGCVLNCTSAQFKCADGSSCINSRYRCDGVYDCRDNSDEAGCPTRPPGMCHLD 1234

Human  1234 EFQCQEDGICIPNFWECDGHPDCLYGSDEHNACVPKTCPSSYFHCDNGNCIHRAWLCDRDNDCGD 1298
            |||||.||.||||.|||||||||::|||||..||||||..::|.|||||||::||:||.||||.|
  Rat  1235 EFQCQGDGTCIPNTWECDGHPDCIHGSDEHTGCVPKTCSPTHFLCDNGNCIYKAWICDGDNDCRD 1299

Human  1299 MSDEKDCPTQPFRCPSWQWQCLGHNICVNLSVVCDGIFDCPNGTDESPLCNGNSCSDFNGGCTHE 1363
            ||||||||||||.|||.||||.|::.|:|||.:|||:||||||||||||||.:|||.|||||||:
  Rat  1300 MSDEKDCPTQPFHCPSTQWQCPGYSTCINLSALCDGVFDCPNGTDESPLCNQDSCSHFNGGCTHQ 1364

Human  1364 CVQEPFGAKCLCPLGFLLANDSKTCEDIDECDILGSCSQHCYNMRGSFRCSCDTGYMLESDGRTC 1428
            |:|.||||.||||||:.||||:||||||:||||.|.|||||.||||||||:||..|.||||||||
  Rat  1365 CMQGPFGATCLCPLGYQLANDTKTCEDINECDIPGFCSQHCVNMRGSFRCACDPEYTLESDGRTC 1429

Human  1429 KVTASESLLLLVASQNKIIADSVTSQVHNIYSLVENGSYIVAVDFDSISGRIFWSDATQGKTWSA 1493
            |||.||:.||:|||::|||.|::|:..||:||||::.|::||:||||::||:||||..||||||.
  Rat  1430 KVTGSENPLLVVASRDKIIVDNITAHTHNLYSLVQDVSFVVALDFDSVTGRVFWSDLLQGKTWSV 1494

Human  1494 FQNGTDRRVVFDSSIILTETIAIDWVGRNLYWTDYALETIEVSKIDGSHRTVLISKNLTNPRGLA 1558
            ||||||:|||.||.:.:||.||:||:|||||||||||||||||||||||||||||||:|.|||||
  Rat  1495 FQNGTDKRVVHDSGLSVTEMIAVDWIGRNLYWTDYALETIEVSKIDGSHRTVLISKNVTKPRGLA 1559

Human  1559 LDPRMNEHLLFWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYPNRLLYFMDSYLDYMD 1623
            |||||.::::||||||||||||||||||:|||||||:||:|||||:|||||||:||||:||||::
  Rat  1560 LDPRMGDNVMFWSDWGHHPRIERASMDGTMRTVIVQEKIYWPCGLSIDYPNRLIYFMDAYLDYIE 1624

Human  1624 FCDYNGHHRRQVIASDLIIRHPYALTLFEDSVYWTDRATRRVMRANKWHGGNQSVVMYNIQWPLG 1688
            ||||:||:|||||||||::.||:|||||||.||||||.||:||:||||||||||||||::..|||
  Rat  1625 FCDYDGHNRRQVIASDLVLHHPHALTLFEDFVYWTDRGTRQVMQANKWHGGNQSVVMYSVHQPLG 1689

Human  1689 IVAVHPSKQPNSVNPCAFSRCSHLCLLSSQGPHFYSCVCPSGWSLSPDLLNCLRDDQPFLITVRQ 1753
            |.|:|||:||.|.||||.:.||||||||:|.|..|||.|||||:||.|.:||:|.|||||::||.
  Rat  1690 ITAIHPSRQPPSRNPCASASCSHLCLLSAQAPRHYSCACPSGWNLSDDSVNCVRGDQPFLMSVRD 1754

Human  1754 HIIFGISLNPEVKSNDAMVPIAGIQNGLDVEFDDAEQYIYWVENPGEIHRVKTDGTNRTVFASIS 1818
            :|||||||:||||||||||||:|||:|.||||||:||:|||||||||||||||||:||||||.:|
  Rat  1755 NIIFGISLDPEVKSNDAMVPISGIQHGYDVEFDDSEQFIYWVENPGEIHRVKTDGSNRTVFAPLS 1819

Human  1819 MVGPSMNLALDWISRNLYSTNPRTQSIEVLTLHGDIRYRKTLIANDGTALGVGFPIGITVDPARG 1883
            ::|.|:.|||||:|||:|.|.|.::|||||||.||.||.|||||||||.||||||:||.||||||
  Rat  1820 LLGSSLGLALDWVSRNIYYTTPASRSIEVLTLKGDTRYGKTLIANDGTPLGVGFPVGIAVDPARG 1884

Human  1884 KLYWSDQGTDSGVPAKIASANMDGTSVKTLFTGNLEHLECVTLDIEEQKLYWAVTGRGVIERGNV 1948
            ||||||.|||||||||||||||||||:|.||||||:|||.|||||:|||||||||.|||||||||
  Rat  1885 KLYWSDHGTDSGVPAKIASANMDGTSLKILFTGNLQHLEVVTLDIQEQKLYWAVTSRGVIERGNV 1949

Human  1949 DGTDRMILVHQLSHPWGIAVHDSFLYYTDEQYEVIERVDKATGANKIVLRDNVPNLRGLQVYHRR 2013
            |||:||||||.|:||||:.|:.|||||:||||||||||||::|.||:|||||||.||||:|||||
  Rat  1950 DGTERMILVHHLAHPWGLVVYGSFLYYSDEQYEVIERVDKSSGNNKVVLRDNVPYLRGLRVYHRR 2014

Human  2014 NAAESSNGCSNNMNACQQICLPVPGGLFSCACATGFKLNPDNRSCSPYNSFIVVSMLSAIRGFSL 2078
            |||:||||||||.|||||||||||||:||||||:||||:||.|||||||||:|||||.|:|||||
  Rat  2015 NAADSSNGCSNNPNACQQICLPVPGGMFSCACASGFKLSPDGRSCSPYNSFMVVSMLPAVRGFSL 2079

Human  2079 ELSDHSETMVPVAGQGRNALHVDVDVSSGFIYWCDFSSSVASDNAIRRIKPDGSSLMNIVTHGIG 2143
            |||||||.||||||||||.||.||||::||||||||||||.|.|.|||||||||:..|:||:|||
  Rat  2080 ELSDHSEAMVPVAGQGRNVLHADVDVANGFIYWCDFSSSVRSSNGIRRIKPDGSNFTNVVTYGIG 2144

Human  2144 ENGVRGIAVDWVAGNLYFTNAFVSETLIEVLRINTTYRRVLLKVTVDMPRHIVVDPKNRYLFWAD 2208
            .||:||:|:||.|||||||||||.||||||||||||||||||||:|||||||:||||:|||||||
  Rat  2145 ANGIRGVALDWAAGNLYFTNAFVYETLIEVLRINTTYRRVLLKVSVDMPRHIIVDPKHRYLFWAD 2209

Human  2209 YGQRPKIERSFLDCTNRTVLVSEGIVTPRGLAVDRSDGYVYWVDDSLDIIARIRINGENSEVIRY 2273
            |||:||||||||||||||||||||||||||||:|...||:||||||||:||||.::|..|:|:||
  Rat  2210 YGQKPKIERSFLDCTNRTVLVSEGIVTPRGLAMDHDTGYIYWVDDSLDLIARIHLDGGESQVVRY 2274

Human  2274 GSRYPTPYGITVFENSIIWVDRNLKKIFQASKEPENTEPPTVIRDNINWLRDVTIFDKQVQPRSP 2338
            |||||||||||||..|||||||||||:|||||:|.||:||.||||.||.||||||||:..||.||
  Rat  2275 GSRYPTPYGITVFGESIIWVDRNLKKVFQASKQPGNTDPPVVIRDKINLLRDVTIFDEHAQPLSP 2339

Human  2339 AEVNNNPCLENNGGCSHLCFALPGLHTPKCDCAFGTLQSDGKNCAISTENFLIFALSNSLRSLHL 2403
            ||:||||||::||||||.|||||.|.||:|.||||||.:|||:||.|.|:|||::|:|||||||.
  Rat  2340 AELNNNPCLQSNGGCSHFCFALPELPTPRCGCAFGTLGNDGKSCATSQEDFLIYSLNNSLRSLHF 2404

Human  2404 DPENHSPPFQTINVERTVMSLDYDSVSDRIYFTQNLASGVGQISYATLSSGIHTPTVIASGIGTA 2468
            ||.:||.|||.|:|..|.::||||..::||:|||.|.|..|||||.:|.||..:|||:.|.||..
  Rat  2405 DPRDHSLPFQVISVAGTAIALDYDRRNNRIFFTQKLNSLRGQISYVSLYSGSSSPTVLLSNIGVT 2469

Human  2469 DGIAFDWITRRIYYSDYLNQMINSMAEDGSNRTVIARVPKPRAIVLDPCQGYLYWADWDTHAKIE 2533
            ||||||||.|||||||:.||.|||||||||||.|||||.||||||||||:||:||.||.|:||||
  Rat  2470 DGIAFDWINRRIYYSDFSNQTINSMAEDGSNRAVIARVSKPRAIVLDPCRGYMYWTDWGTNAKIE 2534

Human  2534 RATLGGNFRVPIVNSSLVMPSGLTLDYEEDLLYWVDASLQRIERSTLTGVDREVIVNAAVHAFGL 2598
            ||||||||||||||:|||.|:||.||.|.|||||.|||||:||||||||.:|||:|:.|.|:|||
  Rat  2535 RATLGGNFRVPIVNTSLVWPNGLALDLETDLLYWADASLQKIERSTLTGTNREVVVSTAFHSFGL 2599

Human  2599 TLYGQYIYWTDLYTQRIYRANKYDGSGQIAMTTNLLSQPRGINTVVKNQKQQCNNPCEQFNGGCS 2663
            |:||||||||||||::||||||||||..:||||.|.:||.||:||||.|:|||:|||:|||||||
  Rat  2600 TVYGQYIYWTDLYTRKIYRANKYDGSDLVAMTTRLPTQPSGISTVVKTQRQQCSNPCDQFNGGCS 2664

Human  2664 HICAPGPNGAECQCPHEGNWYLANNRKHCIVDNGERCGASSFTCSNGRCISEEWKCDNDNDCGDG 2728
            ||||||||||||||||||||||||:.|:|:||.|.||....|||.||.||:::||||||||||||
  Rat  2665 HICAPGPNGAECQCPHEGNWYLANDNKYCVVDTGTRCNQLQFTCLNGHCINQDWKCDNDNDCGDG 2729

Human  2729 SDEMESVCALHTCSPTAFTCANGRCVQYSYRCDYYNDCGDGSDEAGCLFRDCNATTEFMCNNRRC 2793
            |||:.:|||.|||..|||||.|||||.|.|||||||||||.|||||||||:||:||||.|:|.||
  Rat  2730 SDELPTVCAFHTCRSTAFTCGNGRCVPYHYRCDYYNDCGDNSDEAGCLFRNCNSTTEFTCSNGRC 2794

Human  2794 IPREFICNGVDNCHDNNTSDEKNCPDRTCQSGYTKCHNSNICIPRVYLCDGDNDCGDNSDENPTY 2858
            ||..::|||::|||||:||||||||..||...:|||..:|||:||.:||||||||||.|||||.|
  Rat  2795 IPLSYVCNGINNCHDNDTSDEKNCPPHTCPPDFTKCQTTNICVPRAFLCDGDNDCGDGSDENPIY 2859

Human  2859 CTTHTCSSSEFQCAS-GRCIPQHWYCDQETDCFDASDEPASCGHSERTCLADEFKCDGGRCIPSE 2922
            |.:|||.|:||||.| .||||.:|:||.|.||.|.||||.:||||..||.|.:|:||.||||...
  Rat  2860 CASHTCRSNEFQCLSPQRCIPSYWFCDGEADCADGSDEPDTCGHSVNTCRASQFQCDNGRCISGN 2924

Human  2923 WICDGDNDCGDMSDEDKRHQCQNQNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQN 2987
            |:||||||||||||||:||.|:.||||.::|.|||.|||:||||||.||||||.||:|..||.||
  Rat  2925 WVCDGDNDCGDMSDEDQRHHCELQNCSSTQFTCVNSRPPNRRCIPQYWVCDGDADCSDALDELQN 2989

Human  2988 CTRRTCSENEFTCGYGLCIPKIFRCDRHNDCGDYSDERGCLYQTCQQNQFTCQNGRCISKTFVCD 3052
            ||.||||..||:|..|.|:.:.|||||.||||||||||||.|..|..|||||||||||.:.||||
  Rat  2990 CTMRTCSAGEFSCANGRCVRQSFRCDRRNDCGDYSDERGCSYPPCHANQFTCQNGRCIPRFFVCD 3054

Human  3053 EDNDCGDGSDELMHLCHTPEPTCPPHEFKCDNGRCIEMMKLCNHLDDCLDNSDEKGCGINECHDP 3117
            |||||||||||..|||||||||||.|:|:||||.||||.::|||:|||.|||||||||||||.|.
  Rat  3055 EDNDCGDGSDEQEHLCHTPEPTCPLHQFRCDNGHCIEMGRVCNHVDDCSDNSDEKGCGINECLDS 3119

Human  3118 SISGCDHNCTDTLTSFYCSCRPGYKLMSDKRTCVDIDECTEMPFVCSQKCENVIGSYICKCAPGY 3182
            |||.||||||||:|||||||.||||||||||:|||||||.|.|.:||||||||:|||||||||||
  Rat  3120 SISRCDHNCTDTITSFYCSCLPGYKLMSDKRSCVDIDECKESPQLCSQKCENVVGSYICKCAPGY 3184

Human  3183 LREPDGKTCRQNSNIEPYLIFSNRYYLRNLTIDGYFYSLILEGLDNVVALDFDRVEKRLYWIDTQ 3247
            :||||||:||||||||||||||||||:||||.||..|||||:||.||||||||||||||||||.:
  Rat  3185 IREPDGKSCRQNSNIEPYLIFSNRYYIRNLTTDGSSYSLILQGLGNVVALDFDRVEKRLYWIDAE 3249

Human  3248 RQVIERMFLNKTNKETIINHRLPAAESLAVDWVSRKLYWLDARLDGLFVSDLNGGHRRMLAQHCV 3312
            :|:||||||||||:||||||||..||||||||||||||||||.||.||||||.|.||:|:|||||
  Rat  3250 KQIIERMFLNKTNRETIINHRLRRAESLAVDWVSRKLYWLDAILDCLFVSDLEGRHRKMIAQHCV 3314

Human  3313 DANNTFCFDNPRGLALHPQYGYLYWADWGHRAYIGRVGMDGTNKSVIISTKLEWPNGITIDYTND 3377
            ||||||||::|||:.||||.|::||||||..|||||:||||||||||||||:||||.||||||||
  Rat  3315 DANNTFCFEHPRGIVLHPQRGHVYWADWGVHAYIGRIGMDGTNKSVIISTKIEWPNAITIDYTND 3379

Human  3378 LLYWADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFEDTIYWTDWNTRTVEKGNKYDGSNRQ 3442
            |||||||||||||:||||||||||||||:||||||:||||||::||||||||||||||||||.|.
  Rat  3380 LLYWADAHLGYIEFSDLEGHHRHTVYDGSLPHPFALTIFEDTVFWTDWNTRTVEKGNKYDGSGRV 3444

Human  3443 TLVNTTHRPFDIHVYHPYRQPIVSNPCGTNNGGCSHLCLIKPGGKGFTCECPDDFRTLQLSGSTY 3507
            .||||||:||||||||||||||:||||||||||||||||||.||:||||.|||||:|:||...|.
  Rat  3445 VLVNTTHKPFDIHVYHPYRQPIMSNPCGTNNGGCSHLCLIKAGGRGFTCACPDDFQTVQLRDRTL 3509

Human  3508 CMPMCSSTQFLCANNEKCIPIWWKCDGQKDCSDGSDELALCPQRFCRLGQFQCSDGNCTSPQTLC 3572
            ||||||||||||.||||||||||||||||||||||||..|||.||||||||||.||||||||.||
  Rat  3510 CMPMCSSTQFLCGNNEKCIPIWWKCDGQKDCSDGSDEPDLCPHRFCRLGQFQCRDGNCTSPQALC 3574

Human  3573 NAHQNCPDGSDEDRLLCENHHCDSNEWQCANKRCIPESWQCDTFNDCEDNSDEDSSHCASRTCRP 3637
            ||.|:|.|||||||:|||:|.|:|||||||||||||:|||||:.|||.||||||:||||||||||
  Rat  3575 NARQDCADGSDEDRVLCEHHRCESNEWQCANKRCIPQSWQCDSVNDCLDNSDEDTSHCASRTCRP 3639

Human  3638 GQFRCANGRCIPQAWKCDVDNDCGDHSDEPIEECMSSAHLCDNFTEFSCKTNYRCIPKWAVCNGV 3702
            |||:|.|||||||:|||||||||||:|||||:||.::|:.|||.|||||||||||||:||||||.
  Rat  3640 GQFKCNNGRCIPQSWKCDVDNDCGDYSDEPIDECTTAAYNCDNHTEFSCKTNYRCIPQWAVCNGF 3704

Human  3703 DDCRDNSDEQGCEERTCHPVGDFRCKNHHCIPLRWQCDGQNDCGDNSDEENCAPRECTESEFRCV 3767
            |||||||||||||...|||.|||||.|||||||||:|||.:|||||||||||.||||:||||||.
  Rat  3705 DDCRDNSDEQGCESVPCHPSGDFRCANHHCIPLRWKCDGTDDCGDNSDEENCVPRECSESEFRCA 3769

Human  3768 NQQCIPSRWICDHYNDCGDNSDERDCEMRTCHPEYFQCTSGHCVHSELKCDGSADCLDASDEADC 3832
            :||||||||:||..||||||||||||||:|||||:|||||||||...|.|||.|||||||||:.|
  Rat  3770 DQQCIPSRWVCDQENDCGDNSDERDCEMKTCHPEHFQCTSGHCVPKALACDGRADCLDASDESAC 3834

Human  3833 PTRFPDGAYCQATMFECKNHVCIPPYWKCDGDDDCGDGSDEELHLCLDVPCNSPNRFRCDNNRCI 3897
            |||||:|.||.|.||||||||||..:|.|||::||.||||||:|||.::||.||.||||||:||:
  Rat  3835 PTRFPNGTYCPAAMFECKNHVCIQSFWICDGENDCVDGSDEEIHLCFNIPCESPQRFRCDNSRCV 3899

Human  3898 YSHEVCNGVDDCGDGTDETEEHCRKPTPKPCTEYEYKCGNGHCIPHDNVCDDADDCGDWSDELGC 3962
            |.|::||||||||||:||.||||||||.||||:.||||.||:||....|||:.:||||.|||.||
  Rat  3900 YGHQLCNGVDDCGDGSDEKEEHCRKPTHKPCTDTEYKCSNGNCISQHYVCDNVNDCGDLSDETGC 3964

Human  3963 NKGKERTCAENICEQNCTQLNEGGFICSCTAGFETNVFDRTSCLDINECEQFGTCPQHCRNTKGS 4027
            |.|..|||||||||||||||:.|||||||..||:.:..|:.||.||||||:||.|||.|||:|||
  Rat  3965 NLGDNRTCAENICEQNCTQLSSGGFICSCRPGFKPSTLDKNSCQDINECEEFGICPQSCRNSKGS 4029

Human  4028 YECVCADGFTSMSDRPGKRCAAEGSSPLLLLPDNVRIRKYNLSSERFSEYLQDEEYIQAVDYDWD 4092
            |||.|.|||.|||...|:||||:||.||||||:||||||||.|||:|||||::||:||.:|||||
  Rat  4030 YECFCVDGFKSMSTHYGERCAADGSPPLLLLPENVRIRKYNTSSEKFSEYLEEEEHIQTIDYDWD 4094

Human  4093 PKDIGLSVVYYTVRGEGSRFGAIKRAYIPNFESGRNNLVQEVDLKLKYVMQPDGIAVDWVGRHIY 4157
            |:.||||||||||..:||:|||||||||||||||.||.::||||.|||:|||||:||||||||||
  Rat  4095 PEHIGLSVVYYTVLAQGSQFGAIKRAYIPNFESGSNNPIREVDLGLKYLMQPDGLAVDWVGRHIY 4159

Human  4158 WSDVKNKRIEVAKLDGRYRKWLISTDLDQPAAIAVNPKLGLMFWTDWGKEPKIESAWMNGEDRNI 4222
            |||.|::|||||.||||||||||:|.||||||||||||||||||||.||:|||||||||||.|::
  Rat  4160 WSDAKSQRIEVATLDGRYRKWLITTQLDQPAAIAVNPKLGLMFWTDQGKQPKIESAWMNGEHRSV 4224

Human  4223 LVFEDLGWPTGLSIDYLNNDRIYWSDFKEDVIETIKYDGTDRRVIAKEAMNPYSLDIFEDQLYWI 4287
            ||.|:||||.||||||||:||:||||.||||||.|||||||||:|..|||.|:|||||||:|||:
  Rat  4225 LVSENLGWPNGLSIDYLNDDRVYWSDSKEDVIEAIKYDGTDRRLIINEAMKPFSLDIFEDKLYWV 4289

Human  4288 SKEKGEVWKQNKFGQGKKEKTLVVNPWLTQVRIFHQLRYNKSVPNLCKQICSHLCLLRPGGYSCA 4352
            :|||||||:|||||:..|||.|||||||||||||||||||:||.|.|||:|||||||||||||||
  Rat  4290 AKEKGEVWRQNKFGKENKEKVLVVNPWLTQVRIFHQLRYNQSVSNPCKQVCSHLCLLRPGGYSCA 4354

Human  4353 CPQGSSFIEGSTTECDAAIELPINLPPPCRCMHGGNCYFDETDLPKCKCPSGYTGKYCEMAFSKG 4417
            |||||.|:.|||.:||||.|||:.:||||||||||||||||.:||||||.|||:|:|||:..|:|
  Rat  4355 CPQGSDFVTGSTVQCDAASELPVTMPPPCRCMHGGNCYFDENELPKCKCSSGYSGEYCEVGLSRG 4419

Human  4418 ISPGTTAVAVLLTILLIVVIGALAIAGFFHYRRTGSLLPALPKLPSLSSLVKPSENGNGVTFRSG 4482
            |.|||| :|||||.::::::|||.:.|.||||:||||||.||||||||||.||||||||||||||
  Rat  4420 IPPGTT-MAVLLTFVIVIIVGALVLVGLFHYRKTGSLLPTLPKLPSLSSLAKPSENGNGVTFRSG 4483

Human  4483 ADLNMDIGVSGFGPETAIDRSMAMSEDFVMEMGKQPIIFENPMYSARDSAVKVVQPI-------Q 4540
            ||:|||||||.|||||.|||||||:|.||||:||||:|||||||:|:|:..||...:       |
  Rat  4484 ADVNMDIGVSPFGPETIIDRSMAMNEHFVMEVGKQPVIFENPMYAAKDNTSKVALAVQGPSTGAQ 4548

Human  4541 VTVSENVDNKNYGSPINPSEIVPETNPTSPAADGTQVTKWNLFKRKSKQTTNFENPIYAQMENEQ 4605
            |||.|||:|:|||.||:|||||||..|.||.||..|..|||:||||.||||||||||||:|::|.
  Rat  4549 VTVPENVENQNYGRPIDPSEIVPEPKPASPGADEIQGKKWNIFKRKPKQTTNFENPIYAEMDSEV 4613

Human  4606 KESVAATPPPSPSLPAKPKPPSRRDPTPTYSATEDTFKDTANLVKEDSEV 4655
            |::||..||||||||||   .|:|:.||.|:|||||||||||||||||:|
  Rat  4614 KDAVAVAPPPSPSLPAK---ASKRNLTPGYTATEDTFKDTANLVKEDSDV 4660

Known Domains:


Indicated by green bases in alignment.

GeneSequenceDomainRegion External IDIdentity
LRP2NP_004516.2 LDLa 28..62 CDD:238060 23/33 (70%)
LDLa 108..142 CDD:238060 27/33 (82%)
LDLa 149..179 CDD:238060 25/29 (86%)
LDLa 183..217 CDD:238060 24/33 (73%)
LDLa 222..256 CDD:238060 25/33 (76%)
LDLa 266..300 CDD:238060 24/33 (73%)
YncE 394..579 CDD:442618 149/184 (81%)
LDL-receptor class B 1. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 436..478 33/41 (80%)
LDL-receptor class B 2. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 479..521 35/41 (85%)
LY 503..548 CDD:214531 40/44 (91%)
LDL-receptor class B 3. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 522..568 38/45 (84%)
LY 551..591 CDD:214531 33/39 (85%)
LDL-receptor class B 4. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 569..613 38/43 (88%)
FXa_inhibition 663..704 CDD:464251 31/40 (78%)
LDL-receptor class B 5. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 753..795 27/41 (66%)
LY 776..818 CDD:214531 27/41 (66%)
LDL-receptor class B 6. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 796..837 26/40 (65%)
LDL-receptor class B 7. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 838..881 35/42 (83%)
Ldl_recept_b 838..879 CDD:459654 33/40 (83%)
LY 864..904 CDD:214531 33/39 (85%)
LDL-receptor class B 8. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 882..925 34/42 (81%)
FXa_inhibition 981..1013 CDD:464251 25/31 (81%)
LDLa 1026..1060 CDD:238060 24/33 (73%)
LDLa 1067..1101 CDD:238060 21/34 (62%)
LDLa 1109..1143 CDD:238060 25/33 (76%)
LDLa 1149..1183 CDD:238060 24/33 (73%)
LDLa 1187..1222 CDD:238060 23/34 (68%)
LDLa 1230..1264 CDD:238060 27/33 (82%)
LDLa 1271..1305 CDD:238060 23/33 (70%)
LDLa 1311..1344 CDD:197566 22/32 (69%)
FXa_inhibition 1353..1388 CDD:464251 26/34 (76%)
EGF_CA 1390..1429 CDD:214542 30/38 (79%)
LY 1461..1500 CDD:214531 26/38 (68%)
LDL-receptor class B 9. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1478..1520 29/41 (71%)
LY 1501..1543 CDD:214531 33/41 (80%)
LDL-receptor class B 10. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1521..1563 39/41 (95%)
LY 1545..1589 CDD:214531 35/43 (81%)
LDL-receptor class B 11. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1566..1609 35/42 (83%)
LY 1591..1632 CDD:214531 32/40 (80%)
LDL-receptor class B 12. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1610..1654 33/43 (77%)
LDL-receptor class B 13. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1655..1695 30/39 (77%)
YvrE 1787..>1951 CDD:442613 133/163 (82%)
LDL-receptor class B 14. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1790..1832 32/41 (78%)
LDL-receptor class B 15. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1833..1882 36/48 (75%)
LDL-receptor class B 16. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1883..1930 41/46 (89%)
Ldl_recept_b 1883..1928 CDD:459654 39/44 (89%)
LY 1911..1953 CDD:214531 36/41 (88%)
LDL-receptor class B 17. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1931..1972 32/40 (80%)
LDL-receptor class B 18. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1973..2013 32/39 (82%)
FXa_inhibition 2022..2058 CDD:464251 30/35 (86%)
YncE <2091..2252 CDD:442618 133/160 (83%)
LDL-receptor class B 19. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2107..2156 36/48 (75%)
LDL-receptor class B 20. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2157..2201 40/43 (93%)
LDL-receptor class B 21. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2202..2245 39/42 (93%)
LY 2227..2267 CDD:214531 30/39 (77%)
Vgb 2236..2544 CDD:443399 222/307 (72%)
LDL-receptor class B 22. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2246..2289 32/42 (76%)
LDL-receptor class B 23. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2431..2477 28/45 (62%)
LY 2459..2500 CDD:214531 31/40 (78%)
LDL-receptor class B 24. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2478..2518 34/39 (87%)
LY 2500..2542 CDD:214531 34/41 (83%)
LDL-receptor class B 25. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2519..2562 33/42 (79%)
LY 2545..2585 CDD:214531 30/39 (77%)
LDL-receptor class B 26. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2563..2604 30/40 (75%)
LY <2593..2625 CDD:214531 26/31 (84%)
LDL-receptor class B 27. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2605..2646 30/40 (75%)
FXa_inhibition 2655..2692 CDD:464251 33/36 (92%)
LDLa 2700..2732 CDD:238060 22/31 (71%)
LDLa 2741..2775 CDD:238060 27/33 (82%)
LDLa 2784..2817 CDD:238060 22/32 (69%)
LDLa 2821..2854 CDD:197566 21/32 (66%)
Ldl_recept_a 2863..2895 CDD:395011 20/32 (63%)
LDLa 2905..2937 CDD:197566 22/31 (71%)
LDLa 2948..2988 CDD:238060 27/39 (69%)
LDLa 2993..3027 CDD:238060 22/33 (67%)
LDLa 3031..3063 CDD:197566 25/31 (81%)
LDLa 3075..3109 CDD:238060 24/33 (73%)
FXa_inhibition 3121..3150 CDD:464251 25/28 (89%)
vWFA <3147..3190 CDD:469594 35/42 (83%)
LY 3219..3260 CDD:214531 34/40 (85%)
LDL-receptor class B 28. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 3239..3281 34/41 (83%)
LY 3262..3304 CDD:214531 35/41 (85%)
Ldl_recept_b 3282..3330 CDD:459654 37/47 (79%)
LDL-receptor class B 29. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 3282..3324 33/41 (80%)
LDL-receptor class B 30. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 3333..3376 35/42 (83%)
Ldl_recept_b 3333..3374 CDD:459654 33/40 (83%)
LY 3358..3399 CDD:214531 37/40 (93%)
LDL-receptor class B 31. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 3377..3419 38/41 (93%)
LY <3408..3441 CDD:214531 29/32 (91%)
LDL-receptor class B 32. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 3420..3460 33/39 (85%)
FXa_inhibition 3469..>3498 CDD:464251 25/28 (89%)
LDLa 3512..3544 CDD:197566 30/31 (97%)
LDLa 3553..3584 CDD:197566 25/30 (83%)
LDLa 3594..3626 CDD:238060 26/31 (84%)
LDLa 3634..3666 CDD:197566 27/31 (87%)
LDLa 3682..3714 CDD:238060 29/31 (94%)
LDLa 3719..3754 CDD:238060 29/34 (85%)
LDLa 3759..3793 CDD:238060 27/33 (82%)
LDLa 3798..3832 CDD:238060 26/33 (79%)
LDLa 3885..3915 CDD:197566 22/29 (76%)
LDLa 3928..3962 CDD:238060 20/33 (61%)
EGF_CA 4007..4047 CDD:214542 28/39 (72%)
LY 4141..4176 CDD:214531 28/34 (82%)
LDL-receptor class B 33. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 4154..4196 35/41 (85%)
LDL-receptor class B 34. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 4197..4240 34/42 (81%)
Ldl_recept_b 4197..4238 CDD:459654 32/40 (80%)
LY 4222..4264 CDD:214531 33/41 (80%)
LDL-receptor class B 35. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 4242..4283 32/40 (80%)
FXa_inhibition 4338..>4356 CDD:464251 17/17 (100%)
SH3-binding. /evidence=ECO:0000255 4453..4462 7/8 (88%)
PxLPxI/L motif 1, mediates interaction with ANKRA2. /evidence=ECO:0000250|UniProtKB:P98158 4456..4461 3/4 (75%)
PxLPxI/L motif 2, mediates interaction with ANKRA2. /evidence=ECO:0000250|UniProtKB:P98158 4459..4464 4/4 (100%)
Endocytosis signal. /evidence=ECO:0000255 4521..4526 4/4 (100%)
Disordered. /evidence=ECO:0000256|SAM:MobiDB-lite 4550..4574 16/23 (70%)
Interaction with DAB2. /evidence=ECO:0000269|PubMed:10769163 4589..4602 11/12 (92%)
NPXY motif 4595..4598 2/2 (100%)
SH2-binding. /evidence=ECO:0000255 4598..4601 2/2 (100%)
Disordered. /evidence=ECO:0000256|SAM:MobiDB-lite 4601..4655 37/53 (70%)
SH3-binding. /evidence=ECO:0000255 4611..4622 8/10 (80%)
Lrp2NP_110454.2 LDLa 28..62 CDD:238060 23/33 (70%)
LDLa 67..103 CDD:238060 22/35 (63%)
LDLa 108..142 CDD:238060 27/33 (82%)
LDLa 148..179 CDD:238060 25/30 (83%)
LDLa 183..217 CDD:238060 24/33 (73%)
LDLa 222..256 CDD:238060 25/33 (76%)
LDLa 265..299 CDD:238060 24/33 (73%)
YncE <427..576 CDD:442618 122/148 (82%)
LDL-receptor class B 1. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 435..477 33/41 (80%)
LDL-receptor class B 2. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 478..520 35/41 (85%)
LY 502..547 CDD:214531 40/44 (91%)
LDL-receptor class B 3. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 521..567 38/45 (84%)
LY 550..590 CDD:214531 33/39 (85%)
LDL-receptor class B 4. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 568..612 38/43 (88%)
LDL-receptor class B 5. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 752..794 27/41 (66%)
LY 775..817 CDD:214531 27/41 (66%)
LDL-receptor class B 6. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 795..836 26/40 (65%)
LDL-receptor class B 7. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 837..880 35/42 (83%)
Ldl_recept_b 837..878 CDD:459654 33/40 (83%)
LY 863..903 CDD:214531 33/39 (85%)
LDL-receptor class B 8. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 881..924 34/42 (81%)
FXa_inhibition 980..1012 CDD:464251 25/31 (81%)
LDLa 1025..1059 CDD:238060 24/33 (73%)
Ldl_recept_a 1065..1101 CDD:395011 22/35 (63%)
LDLa 1110..1144 CDD:238060 25/33 (76%)
LDLa 1150..1184 CDD:238060 24/33 (73%)
LDLa 1188..1223 CDD:238060 23/34 (68%)
LDLa 1231..1263 CDD:197566 25/31 (81%)
LDLa 1272..1306 CDD:238060 23/33 (70%)
LDLa 1313..1345 CDD:197566 22/31 (71%)
FXa_inhibition 1354..1389 CDD:464251 26/34 (76%)
EGF_CA 1391..1430 CDD:214542 30/38 (79%)
LDL-receptor class B 9. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1479..1521 29/41 (71%)
LY 1502..1544 CDD:214531 33/41 (80%)
LDL-receptor class B 10. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1522..1564 39/41 (95%)
LY 1546..1590 CDD:214531 35/43 (81%)
LDL-receptor class B 11. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1567..1610 35/42 (83%)
LY 1592..1633 CDD:214531 32/40 (80%)
LDL-receptor class B 12. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1611..1655 33/43 (77%)
LDL-receptor class B 13. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1656..1696 30/39 (77%)
FXa_inhibition 1710..1741 CDD:464251 21/30 (70%)
LDL-receptor class B 14. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1791..1833 32/41 (78%)
LDL-receptor class B 15. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1834..1883 36/48 (75%)
LDL-receptor class B 16. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1884..1931 41/46 (89%)
Ldl_recept_b 1884..1929 CDD:459654 39/44 (89%)
LY 1912..1954 CDD:214531 36/41 (88%)
LDL-receptor class B 17. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1932..1973 32/40 (80%)
LDL-receptor class B 18. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 1974..2014 32/39 (82%)
YncE 2035..2253 CDD:442618 182/217 (84%)
LDL-receptor class B 19. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2108..2157 36/48 (75%)
LDL-receptor class B 20. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2158..2202 40/43 (93%)
LDL-receptor class B 21. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2203..2246 39/42 (93%)
LDL-receptor class B 22. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2247..2290 32/42 (76%)
FXa_inhibition 2347..2383 CDD:464251 26/35 (74%)
LDL-receptor class B 23. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2432..2478 28/45 (62%)
LY 2460..2501 CDD:214531 31/40 (78%)
LDL-receptor class B 24. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2479..2519 34/39 (87%)
LDL-receptor class B 25. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2520..2563 33/42 (79%)
Ldl_recept_b 2520..2560 CDD:459654 31/39 (79%)
LY 2546..2586 CDD:214531 30/39 (77%)
LDL-receptor class B 26. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2564..2605 30/40 (75%)
LY <2595..2626 CDD:214531 26/30 (87%)
LDL-receptor class B 27. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 2606..2647 30/40 (75%)
FXa_inhibition 2656..2693 CDD:464251 33/36 (92%)
LDLa 2700..2732 CDD:197566 22/31 (71%)
LDLa 2742..2776 CDD:238060 27/33 (82%)
LDLa 2783..2818 CDD:238060 23/34 (68%)
LDLa 2822..2855 CDD:197566 21/32 (66%)
LDLa 2864..2897 CDD:197566 20/32 (63%)
LDLa 2907..2939 CDD:197566 22/31 (71%)
LDLa 2950..2986 CDD:197566 24/35 (69%)
LDLa 2995..3029 CDD:238060 22/33 (67%)
LDLa 3034..3065 CDD:197566 25/30 (83%)
LDLa 3077..3111 CDD:238060 24/33 (73%)
FXa_inhibition 3124..3152 CDD:464251 25/27 (93%)
EGF_CA 3154..3193 CDD:214542 32/38 (84%)
LY 3221..3263 CDD:214531 35/41 (85%)
LDL-receptor class B 28. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 3241..3283 34/41 (83%)
LY 3264..3306 CDD:214531 35/41 (85%)
Ldl_recept_b 3284..3332 CDD:459654 37/47 (79%)
LDL-receptor class B 29. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 3284..3326 33/41 (80%)
LDL-receptor class B 30. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 3335..3378 35/42 (83%)
Ldl_recept_b 3335..3376 CDD:459654 33/40 (83%)
LY 3360..3401 CDD:214531 37/40 (93%)
LDL-receptor class B 31. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 3379..3421 38/41 (93%)
LY 3402..3443 CDD:214531 36/40 (90%)
LDL-receptor class B 32. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 3422..3462 33/39 (85%)
FXa_inhibition 3471..>3500 CDD:464251 25/28 (89%)
LDLa 3514..3548 CDD:238060 32/33 (97%)
LDLa 3555..3586 CDD:197566 25/30 (83%)
LDLa 3595..3627 CDD:197566 25/31 (81%)
LDLa 3636..3668 CDD:197566 27/31 (87%)
LDLa 3684..3716 CDD:238060 29/31 (94%)
LDLa 3723..3756 CDD:238060 27/32 (84%)
LDLa 3761..3795 CDD:238060 27/33 (82%)
LDLa 3800..3834 CDD:238060 26/33 (79%)
LDLa 3844..3876 CDD:238060 22/31 (71%)
LDLa 3887..3917 CDD:197566 22/29 (76%)
LDLa 3930..3964 CDD:238060 20/33 (61%)
EGF_CA 4009..4049 CDD:214542 28/39 (72%)
LY 4143..4178 CDD:214531 28/34 (82%)
LDL-receptor class B 33. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 4156..4198 35/41 (85%)
LDL-receptor class B 34. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 4199..4242 34/42 (81%)
Ldl_recept_b 4199..4240 CDD:459654 32/40 (80%)
LY 4224..4266 CDD:214531 33/41 (80%)
LDL-receptor class B 35. /evidence=ECO:0000255|PROSITE-ProRule:PRU00461 4244..4285 32/40 (80%)
FXa_inhibition 4340..>4358 CDD:464251 17/17 (100%)
SH3-binding. /evidence=ECO:0000255 4454..4463 7/8 (88%)
PxLPxI/L motif 1, mediates interaction with ANKRA2. /evidence=ECO:0000269|PubMed:22649097 4457..4462 3/4 (75%)
PxLPxI/L motif 2, mediates interaction with ANKRA2. /evidence=ECO:0000269|PubMed:22649097 4460..4465 4/4 (100%)
Endocytosis signal. /evidence=ECO:0000255 4522..4527 4/4 (100%)
Disordered. /evidence=ECO:0000256|SAM:MobiDB-lite 4559..4582 16/22 (73%)
Interaction with DAB2. /evidence=ECO:0000250|UniProtKB:P98164 4597..4610 11/12 (92%)
NPXY motif 4603..4606 2/2 (100%)
SH2-binding. /evidence=ECO:0000255 4606..4609 2/2 (100%)
Disordered. /evidence=ECO:0000256|SAM:MobiDB-lite 4617..4660 34/45 (76%)
SH3-binding. /evidence=ECO:0000255 4619..4630 8/10 (80%)

Return to query results.
Submit another query.